Match!
Mark M. Awad
Harvard University
PathologyOncologyLung cancerCancer researchMedicine
183Publications
34H-index
5,791Citations
What is this?
Publications 207
Newest
#1Biagio Ricciuti (Harvard University)H-Index: 15
#2Abdul Rafeh Naqash (ECU: East Carolina University)H-Index: 5
Last. Gonzalo Recondo (Harvard University)H-Index: 8
view all 23 authors...
Abstract Background The development of immune-related adverse events (irAEs) has been associated with improved efficacy of immune checkpoint inhibitors in patients with urothelial cancer, melanoma, and non-small cell lung cancer. Whether this association exists in patients with small cell lung cancer (SCLC) is currently unknown. Methods We conducted a multicenter retrospective study to evaluate the relationship between irAEs and immunotherapy efficacy in SCLC. To account for the lead-time bias r...
Source
#1Paola CraveroH-Index: 2
Last. Mark M. AwadH-Index: 34
view all 10 authors...
Source
#1Gonzalo Recondo (Harvard University)H-Index: 8
#2Jianwei Che (Harvard University)
Last. Mark M. Awad (Harvard University)H-Index: 34
view all 4 authors...
Aberrant MET signaling can drive tumorigenesis in several cancer types through a variety of molecular mechanisms including MET gene amplification, mutation, rearrangement, and overexpression. Improvements in biomarker discovery and testing have more recently enabled the selection of patients with MET-dependent cancers for treatment with potent, specific, and novel MET-targeting therapies. We review the known oncologic processes that activate MET, discuss therapeutic strategies for MET-dependent ...
Source
#1G. Lamberti (Harvard University)H-Index: 1
#1Giuseppe Lamberti (Harvard University)H-Index: 6
Last. Andrew D. Cherniack (Broad Institute)H-Index: 64
view all 11 authors...
INTRODUCTION: Programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) is the primary clinically-available biomarker of response to immunotherapy in non-small cell lung cancer (NSCLC), but factors associated with PD-L1 expression are not well understood. METHODS: Consecutive nonsquamous NSCLCs with successful PD-L1 assessment and targeted next-generation sequencing (NGS) were included in this retrospective study. Clinicopathological characteristics, gene mutations, and copy number cha...
Source
#1Charles M. Rudin (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 75
#2Mark M. Awad (Harvard University)H-Index: 34
Last. James Chih-Hsin Yang (NTU: National Taiwan University)H-Index: 107
view all 21 authors...
PURPOSEPembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus e...
Source
#1Simon Baldacci (university of lille)H-Index: 5
#1Simon Baldacci (university of lille)H-Index: 1
Last. Alexis B. Cortot (university of lille)H-Index: 13
view all 10 authors...
Abstract: Objective Immune checkpoint inhibitors (ICI) have become a major treatment in advanced non small cell lung cancer (NSCLC). However, some patients do not benefit from ICI, especially those harboring an ALK rearrangement. Here, we report a case of prolonged complete tumor response to immunotherapy in an ALK-rearranged NSCLC patient. Materials and Methods : We verify ALK expression and rearrangement on formalin-fixed paraffin-embedded tumor samples of the patient by Immunohistochemistry a...
Source
#1James Clark (Imperial College London)H-Index: 36
#2Biagio Ricciuti (Harvard University)H-Index: 15
Last. David J. Pinato (Imperial College London)H-Index: 20
view all 9 authors...
Source
#1Gonzalo Recondo (Harvard University)H-Index: 8
#2Robin Guo (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 4
Last. Tom Nguyen (Harvard University)H-Index: 6
view all 14 authors...
Source
#1Biagio Ricciuti (Harvard University)H-Index: 15
#2Christine Champagne (Harvard University)
Last. Mark M. Awad (Harvard University)H-Index: 34
view all 8 authors...
Source
#1Jia Luo (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 2
#2Chaitanya Bandlamudi (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 6
Last. Mark G. Kris (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 105
view all 16 authors...
Source
12345678910